As a first-line treatment, NovoSeven® RT is 92% effective and recommended by an international consensus.
Proven to be effective.
Lower volume means fast infusion.
Because it's a low-volume treatment, NovoSeven® RT takes 2 to 5 minutes to infuse.a
aAdminister as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.
bBased on the initial dose for a 70-kg patient with acute bleeding.
Established safety profile.
Recombinant manufacturing means NovoSeven® RT is made without any human blood or plasma, which minimizes the possibility of viral contamination. And in a clinical trial, 4% of patients with acquired hemophilia experienced adverse events (blood clots).
What if I need surgery or a procedure?
We understand that you have concerns about controlling bleeds if you ever need surgery or a procedure. The good news is that NovoSeven® RT is effective for preventing bleeds during and after surgery and procedures in people with acquired hemophilia.
Talk to your doctor for more information on the surgical use of NovoSeven® RT.
What about surgery and procedures?
Approved for surgical use and procedures for patients with acquired hemophilia.